Tipelukast

October 12, 2015November 5, 2015

MediciNova’s MN-001 (Tipelukast) IPF Therapy Progresses to Phase 2 Clinical Trial

MediciNova, Inc. announced the progression of MN-001 (tipelukast), a small molecule drug to treat idiopathic pulmonary fibrosis (IPF), into phase II clinical trials. This development follows the culmination of the ... Read more

September 11, 2015November 5, 2015

MediciNova’s Experimental IPF Therapy Gets Fast Tracked By US FDA

Idiopathic Pulmonary Fibrosis, News

The US FDA (Food and Drug administration) recently granted a Fast Track designation to MediciNova’s novel drug formulation MN-001 (tipelukast) aimed at treating patients with idiopathic pulmonary fibrosis (IPH). This ... Read more